Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice

Human Gene Therapy

Volumn 12, Issue 15, 2001, Pages 1867-1879

  Willis, Richard A ^a   Bowers, William J ^a   Turner, Michael J ^a   Fisher, Terrence L ^a   Abdul Alim, C Siddiq ^a   Howard, Darlene F ^a   Federoff, Howard J ^a   Lord, Edith M ^a   Frelinger, John G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; MAJOR HISTOCOMPATIBILITY ANTIGEN; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE TRANSFER; GENETIC TRANSDUCTION; HELPER VIRUS; HERPES SIMPLEX VIRUS 1; HYBRIDOMA; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; PLASMID; PROSTATE; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TRANSGENE; TUMOR IMMUNITY; VIRUS CAPSID;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL LINE; CHROMIUM RADIOISOTOPES; COCULTURE TECHNIQUES; DENDRITIC CELLS; EPITHELIAL CELLS; FLOW CYTOMETRY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; HUMANS; HYBRIDOMAS; IMMUNOTHERAPY; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; PLASMIDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 0034779281     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401753153929     Document Type: Article

References (77)

1. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47
2. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
3. Dendritic cells and the control of immunity
4. Immunobiology of dendritic cells
5. Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor
6. Tumor antigens recognized by T cells
7. Discordance between expression and genome transfer titering of HSV amplicon vectors: Recommendation for standardized enumeration
8. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers
9. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
10. Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus
11. Gene-experience interaction alters the cholinergic septo-hippocampal pathway of mice
12. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
13. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants
14. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
15. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
16. In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors
17. Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity
18. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
19. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia
20. Somatic gene transfer approaches to manipulate neural networks
21. Dendritic cells in cancer immunotherapy
22. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope
23. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons
24. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology
25. Cancer statistics, 2000
26. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts
27. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
28. Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens
29. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immuno-genicity in a non-human primate
30. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
31. Neoadjuvant interleukin-12 immunogene therapyrotects against cancer recurrence after liver resection in an animal model
32. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon
33. Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production
34. Eradication of pre-established lym-phoma using herpes simplex virus amplicon vectors
35. Dynamics of T lymphocyte responses: Intermediates, effectors, and memory cells
36. Tumor immunotherapy: Cytokines and antigen presentation
37. Herpes simplex virus type 1 amplicon vectors with glucocorticoid- inducible gene expression
38. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo
39. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
40. Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice
41. Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma
42. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum
43. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(1) T lymphocytes
44. Prostate specific antigen: A decade of discovery-what we have learned and where we are going
45. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome
46. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
47. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells
48. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
49. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
50. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
51. Anti-androgens and other hormonal therapies for prostate cancer
52. A new era for cancer immunotherapy based on the genes that encode cancer antigens
53. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
54. Update on adenovirus and its vectors
55. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: Rescue of replication-competent virus progeny and packaging of amplicon vectors
56. Target antigens for prostate cancer immunotherapy
57. LacZ inducible, antigen/MHC-specific T cell hybrids
58. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells
59. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
60. The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector
61. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
62. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
63. An enhanced packaging system for helper-dependent herpes simplex virus vectors
64. In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester
65. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
66. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP
67. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP
68. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
69. A novel one step protocol for assessing T cell responses using the T cell antigen discovery assay (T-CAD assay): Applications for prostate-specific antigen
70. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
71. Human tumor antigens for cancer vaccine development
72. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes
73. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy
74. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides
75. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen
76. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses
77. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines